( MENAFN - PR Newswire) GERMANTOWN, Md., May 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a webcast on June 3, 2024 at 6:00 PM CT/7:00 PM ET following the late-breaking oral presentation of results from the pivotal study of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
The webcast will include an in-depth review of the PRGN-2012 pivotal data and business update. Phase 2 study results will be presented on June 3rd at 8:30 AM CT during ASCO in a presentation titled, "PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients " by Scott M. Norberg, DO, Associate Research Physician, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute and a lead investigator for the PRGN-2012 Phase 2 clinical study.
Participants may register and access the webcast through Precigen's website in the Events & Presentations section. An archived recording will be posted to the website following the event. Precigen: Advancing Medicine with PrecisionTM Precigen (Nasdaq: PGEN ) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generat.